Page 29 - RA_Centre_Paul_STRAUSS_2017

42. Keller A ; Doré M ; Antoni D ; Menoux population-based study of individual data 68. Gueyffier F ; Piedbois P ; Bergmann JF. French web-based survey, MAbs, 2017, 9,
I ; Thillays F ; Clavier JB & al. Risk of radio- for 89828 children from 198 registries in 53 Therapie, 2017, 72, 39-49 (Dufour, Patrick) 383-390 (velten, Michel) – B
necrosis after hypofractionated stereotactic countries, Lancet Haematol, 2017, 4, e202- – E
radiotherapy targeting the postoperative e217 (velten, Michel) – A 82. Matz M ; Coleman MP ; Carreira H ;
resection cavity of brain metastases, Can- 69. Gueyffier F ; Piedbois P ; Bergmann Salmerón D ; Chirlaque MD ; Allemani C.
cer Radiother, 2017, 21, 377-388 (Noël, 55. Steliarova-Foucher E ; Colombet M ; JF. How to measure the net benefit of treat- Worldwide comparison of ovarian cancer
Georges) – E Ries LAG ; Moreno F ; Dolya A ; Bray F & ment? Therapie, 2017, 72, 51-61 (Dufour, survival : Histological group and stage at
al. International incidence of childhood can- Patrick) – E diagnosis (CONCORD-2), Gynecol Oncol,
43. Gligorov J ; Curigliano G ; Müller cer, 2001-10: a population-based registry 2017, 144, 396-404 (velten, Michel) – B
v ; Knoop A ; Jenkins v ; verma S & al. study, Lancet Oncol, 2017, 18, 719-731 70. Bobin M ; Zacharatou C ; Sargos P ;
Switching between intravenous and subcu- (velten, Michel) – B Brouste v ; Lisbona A ; Mahé MA & al. 83. Guihard S ; Thariat J ; Clavier JB. Big
taneous trastuzumab : Safety results from the Helical tomotherapy of spinal chordomas : data and their perspectives in radiation the-
PrefHer trial, Breast, 2017, 34, 89-95 (Pivot, 56. Dal Maso L ; Tavilla A ; Pacini F ; Ser- French Multicentric, retrospective study of a rapy, Bull Cancer, 2017, 104, 147-156 – E
Xavier) – C raino D ; van Dijk BAC ; Chirlaque MD & cohort of 30 cases, Radiat Oncol, 2017, 12,
al. Survival of 86690 patients with thyroid 32 (Noël, Georges) – C 84. Boulanger M ; Tual S ; Lemarchand C
44. Bockel S ; Antoni D ; Deutsch é ; Mor- cancer : A population-based study in 29 ; Guizard Av ; velten M ; Marcotullio E &
nex F. Immunotherapy and radiotherapy, European countries from EUROCARE-5, 71. Charlier C ; Perrodeau é ; Leclercq A ; al. Agricultural exposure and risk of bladder
Cancer Radiother, 2017, 21, 244-255 – E Eur J Cancer, 2017, 77, 140-152 (velten, Cazenave B ; Pilmis B ; Henry B & al. Clini- cancer in the AGRIculture and CANcer co-
Michel) – B cal features and prognostic factors of liste- hort, Int Arch Occup Environ Health, 2017,
45. viot J ; Bachour M ; Meurisse A ; Pivot riosis : the MONALISA national prospective 90, 169-178 – C
X ; Fiteni F. Follow-up of patients with loca- 57. Leduc C ; Antoni D ; Charloux A ; cohort study, Lancet Infect Dis, 2017, 17,
lized breast cancer and first indicators of ad- Falcoz PE ; Quoix E. Comorbidities in the 510-519 (Merrouche, Yacine) – A 85. Nerich v ; Fleck C ; Chaigneau L ;
vanced breast cancer recurrence : A retros- management of patients with lung cancer, Isambert N ; Borg C ; Kalbacher E & al.
pective study, Breast, 2017, 34, 53-57 – C Eur Respir J, 2017, 49 – A 72. Moitry M ; velten M ; Trétarre B ; Bara Cost-Effectiveness Analysis of Tyrosine
S ; Daubisse-Marliac L ; Lapôtre-Ledoux B Kinase Inhibitors for Patients with Advanced
46. Paix A ; Antoni D ; Adeduntan R ; Noël 58. Menoux I ; Guihard S ; Antoni D ; Bijon & al. Development of a model to predict the Gastrointestinal Stromal Tumors, Clin Drug
G. Stereotactic radiation therapy of brain JC ; Noël G. Choroidal metastasis from a 10-year cumulative risk of second primary Investig, 2017, 37, 85-94 (Pivot, Xavier) – D
metastases from colorectal cancer : A single lung adenocarcinoma treated by intravitreal cancer among cancer survivors, Cancer Epi-
institution cohort, Cancer Radiother, 2017, injection of anti-vEGF and external beam demiol, 2017, 47, 35-41 – D 86. Dupont B ; Mariotte D ; Dugué AE ; Cla-
21, 199-204 – E radiotherapy : A case report, Cancer Radio- risse B ; Grellard JM ; Babin E & al. Utility
ther, 2017, 21, 130-133 – E 73. Eisinger F ; Pivot X ; Greillier L ; Cou- of serum anti-cetuximab immunoglobulin E
47. Pougnet I ; Jaegle E ; Garcia R ; Tessier raud S ; Cortot AB ; Touboul C & al. Cancer levels to identify patients at a high risk of se-
F ; Faivre JC ; Louvel G & al. Spinal stereo- 59. Jéhannin-Ligier K ; Dejardin O ; Lapôtre- screening in France : 10 years of analysis vere hypersensitivity reaction to cetuximab,
tactic body radiotherapy: French assessment Ledoux B ; Bara S ; Coureau G ; Grosclaude of behaviours by the EDIFICE surveys, Bull Br J Clin Pharmacol, 2017, 83, 623-631
in 2016, Cancer Radiother, 2017, 21, 276- P & al. Oral cancer characteristics in France: Cancer, 2017, 104, 258-266 – E (Schott, Roland) – B
285 (Clavier, Jean-Baptiste) – E Descriptive epidemiology for early detection,
J Stomatol Oral Maxillofac Surg, 2017, 74. Curtit E ; Mansi L ; Maisonnette-Escot 87. Bielle F ; Ducray F ; Mokhtari K ; Dehais
48. Demoor-Goldschmidt C ; Drui D ; Dou- 118, 84-89 (velten, Michel) – E Y ; Sautière JL ; Pivot X. Breast Recurrence C ; Adle-Biassette H ; Carpentier C & al. Tu-
triaux I ; Michel G ; Auquier P ; Dumas A Score Assay, Eur J Surg Oncol, 2017, 43, mor cells with neuronal intermediate proge-
& al. A French national breast and thyroid 60. velter C ; Caussade P ; Fricker JP ; Cri- 921-930 – C nitor features define a subgroup of 1p/19q
cancer screening programme for survivors bier B. Muir-Torre syndrome and Turcot syn- co-deleted anaplastic gliomas, Brain Pathol,
of childhood, adolescent and young adult drome, Ann Dermatol venereol, 2017, 144, 75. Marrer é ; Jolly D ; Arveux P ; Lejeune 2017, 27, 567-579 (Noël, Georges) – A
(CAYA) cancers - DeNaCaPST programme, 525-529 – E C ; Woronoff-Lemsi MC ; Jégu J & al.
BMC Cancer, 2017, 17, 326 (vigneron, Incidence of solitary pulmonary nodules in 88. Raguin T ; Schneegans O ; Rodier JF
Céline) – C 61. Krummel T ; Thiery A ; villain M ; Northeastern France: a population-based ; volkmar PP ; Sauleau E ; Debry C & al.
Schittly B ; Brouant B. Psychotropic Drug Use study in five regions, BMC Cancer, 2017, Value of fine-needle aspiration in evaluating
49. Nerich v ; Saing S ; Gamper EM ; in Recreational Scuba Divers and its Effect 17, 47 (velten, Michel) – C large thyroid nodules, Head Neck, 2017,
Holzner B ; Pivot X ; viney R & al. Critical on Severe Narcosis, Int J Sports Med, 2017, 39, 32-36 (Ghnassia, Jean-Pierre) – B
appraisal of health-state utility values used 38, 322-328 – C 76. Carton M ; Barul C ; Menvielle G ; Cyr D
in breast cancer-related cost-utility analyses, ; Sanchez M ; Pilorget C & al. Occupational 89. Chouaid C ; Falchero L ; Schott R ; Bon-
Breast Cancer Res Treat, 2017, 164, 527- 62. Merklen-Djafri C ; Truntzer P ; Hassler exposure to solvents and risk of head and netain F ; Taguieva-Pioger N ; Bennouna J.
536 – C S ; Cribier B. Increased glucose uptake by neck cancer in women : a population-based Bevacizumab in combination with first-line
seborrheic keratosis on PET scan, Ann Der- case-control study in France, BMJ Open, treatment for metastatic non-small cell lung
50. Etienne-Grimaldi MC ; Boyer JC ; matol venereol, 2017, 144, 378-382 – E 2017, 7, e012833 (velten, Michel) – B cancer in clinical practice. Results of the
Beroud C ; Mbatchi L ; van Kuilenburg A ; EOLE study, Rev Mal Respir, 2017, 34, 36-
Bobin-Dubigeon C & al. New advances in 63. Paix A ; Waissi W ; Antoni D ; Adedun- 77. Perez EA ; Barrios C ; Eiermann W ; 43 – E
DPYD genotype and risk of severe toxicity tan R ; Noël G. visceral and bone metas- Toi M ; Im YH ; Conte P & al. Trastuzumab
under capecitabine, PLoS One, 2017, 12, tases of a WHO grade 2 meningioma : A Emtansine With or Without Pertuzumab 90. Thiery A ; Akladios C ; Fender M ;
e0175998 (Pivot, Xavier) – B case report and review of the literature, Can- versus Trastuzumab Plus Taxane for Human Severac F ; Baldauf JJ. Excess cervical
cer Radiother, 2017, 21, 55-59 – E Epidermal Growth Factor Receptor 2-Posi- cancer screening smears : Any benefit? A
51. Lebellec L ; Chauffert B ; Blay JY ; Le tive, Advanced Breast Cancer: Primary Re- retrospective cohort in Alsace, France, J Med
Cesne A ; Chevreau C ; Bompas E & al. 64. Pivot X, Classic cytotoxic drugs : a nar- sults From the Phase III MARIANNE Study, Screen, 2017, 24, 92-97 – C
Advanced chordoma treated by first-line row path for regulatory approval. Lancet J Clin Oncol, 2017, 35, 141-148 (Pivot,
molecular targeted therapies : Outcomes Oncol, 2017, 18, 279-281 – A Xavier) – A 91. Werlé F, Dehaynin N, Niederst C, Jar-
and prognostic factors. A retrospective study net D, Gantier M, Karamanoukian D, Meyer
of the French Sarcoma Group (GSF/GETO) 65. Arbor N ; Higueret S ; Elazhar H ; 78. Salaün H ; Thariat J ; vignot M ; Mer- P. Detecting anomalies in a deliberately
and the Association des Neuro-Oncolo- Combe R ; Meyer P ; Dehaynin N & al. Real- rouche Y ; vignot S. Obesity and cancer, biased tomotherapy plan: Comparison of
gues d'Expression Française (ANOCEF), time detection of fast and thermal neutrons Bull Cancer, 2017, 104, 30-41 – E two patient-specific quality assurance pro-
®
Eur J Cancer, 2017, 79, 119-128 (Noël, in radiotherapy with CMOS sensors, Phys cesses involving ArcCHECK and Gafchro-
Georges) – B Med Biol, 2017, 62, 1920-1934 – C 79. Bell R ; Brown J ; Parmar M ; Toi M ; mic EBT3 films, 2017, 21(8):749-758 – E
®
Suter T ; Steger GG & al. Final efficacy and
52. Mirghani H ; Jung AC ; Fakhry C. Pri- 66. Meynard G ; Mansi L ; Lebahar P ; updated safety results of the randomized 92. Pivot, X ; Verma, S ; Fallowfield, L ;
mary, secondary and tertiary prevention villanueva C ; Klaje E ; Calcagno F & al. phase III BEATRICE trial evaluating adjuvant Müller, v ; Lichinitser, M ; Jenkins, v & al.
of human papillomavirus-driven head and First description of a double heterozygosity bevacizumab-containing therapy in triple- Efficacy and safety of subcutaneous tras-
neck cancers, Eur J Cancer, 2017, 78, 105- for BRCA1 and BRCA2 pathogenic variants negative early breast cancer, Ann Oncol, tuzumab and intravenous trastuzumab as
115 – B in a French metastatic breast cancer patient: 2017, 28, 754-760 (Pivot, Xavier) – A part of adjuvant therapy for HER2-positive
A case report, Oncol Rep, 2017, 37, 1573- early breast cancer : Final analysis of the
53. Burgy M ; Barthélémy P ; Lefevre F ; 1578 (Pivot, Xavier) – D 80. Matz M ; Coleman MP ; Sant M ; Chir- randomised, two-cohort PrefHer study,
Dupret-Bories A ; Truntzer P ; Korenbaum C laque MD ; visser O ; Gore M & al. The 10.1016/j.ejca.2017.08.019
& al. Cetuximab-Carboplatin-5-Fluorouracil 67. Pierga JY ; Bidard FC ; Autret A ; Petit T ; histology of ovarian cancer : worldwide
Regimen in Elderly Patients with Recurrent or Andre F ; Dalenc F & al. Circulating tumour distribution and implications for internatio- 93. Pivot, X ; Cox, DG ; Gligorov, J. Why
Metastatic Head and Neck Squamous-Cell cells and pathological complete response: nal survival comparisons (CONCORD-2), the results of adjuvant pertuzumab in
Carcinoma : A French Retrospective Survey, independent prognostic factors in inflam- Gynecol Oncol, 2017, 144, 405-413 (vel- HER2-positive early breast cancer has been
Oncology, 2017, 93, 11-17 – D matory breast cancer in a pooled analysis ten, Michel) – B received as a mitigate success ? 10.21037/
of two multicentre phase II trials (BEvERLY-1 cco.2017.10.07
54. Bonaventure A ; Harewood R ; Stiller and -2) of neoadjuvant chemotherapy com- 81. Beck M ; Michel B ; Rybarczyk-vigou-
CA ; Gatta G ; Clavel J ; Stefan DC & al. bined with bevacizumab, Ann Oncol, 2017, ret MC ; Levêque D ; Sordet C ; Sibilia J
Worldwide comparison of survival from 28, 103-109 – A & al. Knowledge, behaviors and practices
childhood leukaemia for 1995-2009, by of community and hospital pharmacists
subtype, age, and sex (CONCORD-2) : a towards biosimilar medicines : Results of a

| 27